Table 2.
Clinical characteristics at time of diagnosis of LCCN
| Characteristic | Patients (n = 178) |
|---|---|
| Demographic characteristics | |
| Age, y | 66 ± 11 |
| Ethnicity, % white, AA, Asian, Middle Eastern, other | 90, 6, 1, 1, 2 |
| Female sex, % | 45 |
| Medical history | |
| Hypertension, % | 40 |
| Congestive heart failure, % | 2.3 |
| Vascular disease, % | 16 |
| Diabetes, % | 14 |
| Myeloma characteristics | |
| Prior chemotherapy for myeloma, % | 7.3 |
| Type of myeloma, % | |
| IgG | 26 |
| IgA | 21 |
| IgD | 3 |
| IgM | 2 |
| LC only | 48 |
| Size of monoclonal spike, g/L | 12 (3-32) |
| FLC level, mg/L | 5010 (2780-10 504) |
| κ/λ, % | 47/53 |
| Bone marrow plasma cells % | 50 (27-75) |
| Hemoglobin, g/L | 92 ± 17 |
| LDH, U/L | 270 ± 145 |
| β2-microglobulin, mg/L | 13 (7-22) |
| Presence of lytic bone lesions, % | 63 |
| Renal characteristics | |
| eGFR before LCCN, mL/min/1.73 m2 | 76 ± 27 |
| eGFR, mL/min/1.73m2 | 13 ± 11 |
| AKIN stage (0, 1, 2, 3) | 1, 5, 12, 82 |
| Dialysis dependence, % | 47 |
| Albumin, g/L | 34 ± 6 |
| Albuminuria, % | 9 (5-16) |
| Proteinuria, g/d | 2.2 (1.2-4.4) |
| Additional risk factors for AKI | |
| Infection at diagnosis of LCCN, % | 24 |
| Nephrotoxic drugs, % | 27 |
| Contrast media, % | 5.1 |
| Hypercalcemia, % | 24 |
| Any additional risk factor for AKI, % | 61 |
Missing data were as follows: size of monoclonal spike, 15%; FLC, 5%; % bone marrow plasma cells, 18%; lactic acid dehydrogenase (LDH), 21%; β2-microglobulin, 33%; lytic lesions, 11%; eGFR before LCCN, 29%.
AA, African American; Ig, immunoglobulin.